Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Xentuzumab |
| Trade Name | |
| Synonyms | BI 836845 |
| Drug Descriptions |
Xentuzumab (BI 836845) is a monoclonal antibody that binds to IGF-1 and IGF-2 and prevents binding to the IGF receptor (IGF-1R), resulting in decreased IGF-1R signaling (PMID: 32161368, PMID: 32054790). |
| DrugClasses | IGF1/2 Antibody 2 |
| CAS Registry Number | 1417158-65-6 |
| NCIT ID | C106118 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Abemaciclib + Anastrozole + Xentuzumab | Abemaciclib Anastrozole Xentuzumab | 0 | 1 |
| Abemaciclib + Fulvestrant + Xentuzumab | Abemaciclib Fulvestrant Xentuzumab | 0 | 1 |
| Abemaciclib + Letrozole + Xentuzumab | Abemaciclib Letrozole Xentuzumab | 0 | 1 |
| Abemaciclib + Xentuzumab | Abemaciclib Xentuzumab | 0 | 1 |
| Cisplatin + Xentuzumab | Cisplatin Xentuzumab | 0 | 0 |
| Everolimus + Exemestane + Xentuzumab | Everolimus Exemestane Xentuzumab | 0 | 1 |
| PHA-665752 + Xentuzumab | PHA-665752 Xentuzumab | 0 | 0 |
| Xentuzumab | Xentuzumab | 0 | 2 |